Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Burkitt Lymphoma 7Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Down Syndrome 2Leukemia, Plasma Cell 1Leukemia, Biphenotypic, Acute 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 9ibrutinib 6acalabrutinib 6Cyclophosphamide 6zanubrutinib 4venetoclax 4fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Methotrexate 3Magnetic Resonance Spectroscopy 3Cytarabine 3Cyclosporine 3CT-P10 3Bendamustine Hydrochloride 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Vincristine 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Etoposide 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2treosulfan 1pirtobrutinib 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × dexamethasone acetate × 30 days × Clear all
NCT02427620 2026-05-22

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
131 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT03710772 2026-05-19

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
51 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡